Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer

European Journal of Dermatology

Volumn 19, Issue 5, 2009, Pages 461-468

  Uchi, Hiroshi ^a   Igarashi, Atsuyuki ^b   Urabe, Kazunori ^a   Koga, Tetsuya ^c   Nakayama, Juichiro ^d   Kawamori, Ryuzo ^e   Tamaki, Kunihiko ^f   Hirakata, Hideki ^c   Ohura, Takehiko ^g   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b Kanto Teishin Hospital   (Japan)

^c FUKUOKA RED CROSS HOSPITAL   (Japan)

^d FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g Wound Healing Research Center   (Japan)

Author keywords

Basic fibroblast growth factor; Diabetic ulcer; Randomized trial

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PLACEBO;

ADMINISTRATION SITE PAIN; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ULCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EXUDATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; TREATMENT DURATION; ULCER HEALING; WOUND INFECTION;

ADULT; AGED; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED;

EID: 69849084385     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0750     Document Type: Article

References (22)

1. Goodson 3rd WH, Hunt TK. Wound healing and the diabetic patient. Surg Gynecol Obstet 1979; 49: 600-608
2. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746
3. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998; 111: 850-857 (Pubitemid 28509329)
4. Dinh TL, Veves A. A review of the mechanisms implicated in the pathogenesis of the diabetic foot. Int J Low Extrem Wounds 2005; 4: 154-159 (Pubitemid 41437582)
5. Wieman TJ, Griffiths GD, Polk Jr HC, et al. Management of diabetic midfoot ulcers. Ann Surg 1992; 215: 627-632
6. Bohlen P, Baird A, Esch F, Ling N, Gospodarowicz D. Isolation and partial molecular characterization of pituitary fibroblast growth factor. Proc Natl Acad Sci USA 1984; 81: 5364-5368 (Pubitemid 14048748)
7. Thomas K, Rios-Candelore M, Fitzpatrick S. Purification and characterization of acidic fibroblast growth factor from bovine brain. Proc Natl Acad Sci USA 1984; 81: 357-361 (Pubitemid 14185728)
8. Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J 1986; 5: 2523-2528
9. Baird A, Bohlen P. Fibroblast growth factors. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors I. Heidelberg: Springer-Verlag, 1991: 369-418.
10. Ueno N, Baird A, Esch F, Ling N, Guillemin R. Isolation of an amino terminal extended form of basic fibroblast growth factor. Biochem Biophys Res Commun 1986; 138: 580-588 (Pubitemid 16013178)
11. Story MT, Esch F, Shimasaki S, Sasse J, Jacobs SC, Lawson RK. Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue. Biochem Biophys Res Commun 1987; 142: 702-709 (Pubitemid 17021092)
12. Baird A, Esch F, Mormede P, et al. Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. Recent Prog Horm Res 1986; 42: 143-205.
13. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med 1990; 172: 245-251 (Pubitemid 20217266)
14. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990; 136: 1235-1246 (Pubitemid 20210322)
15. Hayward P, Hokanson J, Heggers J, et al. Fibroblast growth factor reserves the bacterial retardation of wound contraction. Am J Surg 1992; 163: 288-293 (Pubitemid 23072507)
16. Ishibashi Y, Soeda S, Ohura T, et al. Clinical effects of KCB-1, a solution of recombinant human basic fibroblast growth factor, on skin ulcers - A phase III study comparing with sugar and povidone iodine ointment. J Clin Ther Med (in Japanese) 1996; 12: 2159-2187
17. Okumura M, Okuda T, Nakamura T, Yajima M. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol Pharm Bull 1995; 19: 530-535 (Pubitemid 26144609)
18. Nevins M, Giannobile WV, McGuire MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodonto 2005; 76: 2205-2215 (Pubitemid 43116085)
19. Pierce GF, Tarpley JE, Allman RM, et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 1994; 145: 1399-1410
20. Mustoe TA, Cutler NR, Allman RM, et al. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129: 213-219
21. Hong JP, Kim YW, Jung HD, Jung KI. The effect of various concentrations of human recombinant epidermal growth factor on splitthickness skin wounds. Int Wound J 2006; 3: 123-130 (Pubitemid 44400783)
22. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827 (Pubitemid 28487079)